Talis Biomedical (NASDAQ:TLIS) Trading Up 0.8% – Time to Buy?

Talis Biomedical Co. (NASDAQ:TLIS) shot up 0.8% on Friday . The company traded as high as $1.71 and last traded at $1.71. 402 shares were traded during mid-day trading, a decline of 97% from the average session volume of 12,678 shares. The stock had previously closed at $1.70.

Talis Biomedical Trading Up 0.8 %

The company’s 50-day moving average price is $1.75 and its two-hundred day moving average price is $4.05. The company has a market cap of $3.12 million, a P/E ratio of -0.06 and a beta of 1.58.

Institutional Investors Weigh In On Talis Biomedical

A hedge fund recently raised its stake in Talis Biomedical stock. BML Capital Management LLC grew its position in Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 248,702 shares of the company’s stock after buying an additional 205,959 shares during the quarter. Talis Biomedical makes up approximately 0.3% of BML Capital Management LLC’s portfolio, making the stock its 24th largest position. BML Capital Management LLC owned approximately 13.66% of Talis Biomedical worth $460,000 at the end of the most recent reporting period. 43.77% of the stock is currently owned by hedge funds and other institutional investors.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.